Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project

Literature DB >> 23125546

Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.

Carmino Antonio de Souza¹, Katia Borgia Barbosa Pagnano, Israel Bendit, Monika Conchon, Carla Maria Boquimpani de Moura Freitas, Arthur Moellmann Coelho, Vaneuza Araújo Moreira Funke, Wanderley Marques Bernardo.

Abstract

Entities: Chemical Disease Gene Mutation Species

Year: 2012 PMID： 23125546 PMCID： PMC3486828 DOI： 10.5581/1516-8484.20120094

Source DB: PubMed Journal: Rev Bras Hematol Hemoter ISSN： 1516-8484

× No keyword cloud information.

101 in total

1. Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia.

Authors: Mireille Guimarães Vaz de Campos; Fábio Tadeu Montesano; Maria Madalena Rodrigues; Maria de Lourdes Lopes Ferrari Chauffaille
Journal: Cancer Genet Cytogenet Date: 2007-10-01

Review 2. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors: M Baccarani; M Dreyling
Journal: Ann Oncol Date: 2009-05 Impact factor: 32.976

3. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia.

Authors: Nasios Fourouclas; Peter J Campbell; Anthony J Bench; Soheila Swanton; E Joanna Baxter; Brian Jp Huntly; Anthony R Green
Journal: Haematologica Date: 2006-07 Impact factor: 9.941

4. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Authors: E Jabbour; H Kantarjian; D Jones; M Talpaz; N Bekele; S O'Brien; X Zhou; R Luthra; G Garcia-Manero; F Giles; M B Rios; S Verstovsek; J Cortes
Journal: Leukemia Date: 2006-07-20 Impact factor: 11.528

5. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia.

Authors: Massimo Breccia; Caterina Stefanizzi; Laura Cannella; Roberto Latagliata; Anna Maria Frustaci; Ida Carmosino; Michelina Santopietro; Giuliana Alimena
Journal: Leuk Lymphoma Date: 2008-12

6. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.

Authors: Andrew P Landstrom; Ryan A Knudson; Gordon W Dewald; Rhett P Ketterling; Ayalew Tefferi
Journal: Leuk Lymphoma Date: 2007-11

7. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

Authors: D M Ross; S Branford; S Moore; T P Hughes
Journal: Leukemia Date: 2006-04 Impact factor: 11.528

8. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

Authors: Susan Branford; Linda Fletcher; Nicholas C P Cross; Martin C Müller; Andreas Hochhaus; Dong-Wook Kim; Jerald P Radich; Giuseppe Saglio; Fabrizio Pane; Suzanne Kamel-Reid; Y Lynn Wang; Richard D Press; Kevin Lynch; Zbigniew Rudzki; John M Goldman; Timothy Hughes
Journal: Blood Date: 2008-08-06 Impact factor: 22.113

Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012.

1. Clinical implications of der(9q) deletions detected through dual-fusion fluorescence in situ hybridization in patients with chronic myeloid leukemia.

Review 2. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up.

3. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia.

4. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

5. Differences in hematological and non-hematological toxicity during treatment with imatinib in patients with early and late chronic phase chronic myeloid leukemia.

6. Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.

7. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.

8. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

9. Prognostic relevance of 9q34 deletion and the suppressor of cytokine signalling-1 in CML patients.

10. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.

1. Goals, globalization and the impact factor of the journal.

2. Reviews and guidelines: Evidence of progress and a starting point for standardization and changes.

3. The Guidelines Project: Brazilian guidelines for acute promyelocytic leukemia.

4. BCR-ABL1 level monitoring in chronic myeloid leukemia by real time polymerase chain reaction in Brazil - not so real.

5. Five years of implementation of guidelines in hematology and transfusion medicine in Brazil.